Also don't forget the background of the historic AML trials. An average Complete Response of 51% in Phase II trials that reported results between 1987 and 1994 [1]. It's a background that IMO potentially supports further confidence of a strong result in the Israel aka Sheba 2.0 trial.
[1] https://raceoncology.com/wp-content...e-a-review-of-the-literature-ijcrt-17-015.pdf
It was this historic consistency in performance that caused Dr T to stop and take a very careful look at Bisantrene when he reviewed ASX biotech tickers in alphabetical sequence in early 2019.
Also don't forget the background of the historic AML trials. An...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
-0.005(0.40%) |
Mkt cap ! $204.3M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.21 | $120.5K | 97.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 991 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 2409 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.24 |
Change
-0.005 ( 0.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.24 | $1.25 | $1.21 | 17303 | ||
| Last updated 15.51pm 02/05/2024 ? | |||||
| RAC (ASX) Chart |